Jiangsu Hengrui Medicine buys back shares for employee stock plan

Jiangsu Hengrui Medicine, listed on the Shanghai Stock Exchange, announced a share buyback activity dated November 10, 2025. The company repurchased 60,000 A-shares, which are to be held as treasury stock for its A-share employee stock ownership plan. The transaction was conducted on the Shanghai Stock Exchange, at a price range of RMB 61.31 (highest) to RMB 61 (lowest) per share. The total cost for this buyback amounted to RMB 3,668,376.

Following this repurchase, the number of issued A-shares (excluding treasury shares) for Jiangsu Hengrui Medicine decreased by 60,000 to 6,375,873,264 as of November 10, 2025. Concurrently, the number of treasury shares increased by 60,000 to 3,129,010. This buyback represents a 0.0009% change in the company's issued share capital (excluding treasury shares) relative to its balance on November 7, 2025, which was 6,375,933,264 shares.

The total number of issued shares, including treasury shares, remains at 6,379,002,274 as of November 10, 2025. The company confirmed that this buyback activity was conducted in accordance with the applicable rules for share repurchases on that exchange.